Physician profile
Narcisa E Murillo
NPI 1942282306
$12,129.23
in general payments reported to CMS, 2019-2025
38 companies · $697 in 2025
The $697 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,272 · 2020: $1,719 · 2021: $1,523 · 2022: $1,985 · 2023: $2,579 · 2024: $1,354 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,367 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,366.76 |
| Education | $263.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,040.84 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,918.91 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $1,185.05 | 2019-2025 | Prolia, Evenity, Otezla |
| Glaxosmithkline, LLC. | $1,102.11 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,007.05 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $928.33 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $677.95 | 2019-2025 | Verquvo, Lagevrio, Steglatro |
| Lilly USA, LLC | $460.13 | 2019-2023 | Jardiance |
| Astellas Pharma US INC | $417.66 | 2019-2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $338.28 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $297.57 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $261.58 | 2019-2023 | Linzess |
| Amarin Pharma, INC. | $236.28 | 2019-2022 | |
| Radius Health, INC. | $170.08 | 2019-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.39 | 2021-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narcisa Murillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.